Zoetis Inc. (ETR:ZOE)
| Market Cap | 46.78B |
| Revenue (ttm) | 8.01B |
| Net Income (ttm) | 2.26B |
| Shares Out | n/a |
| EPS (ttm) | 5.06 |
| PE Ratio | 20.70 |
| Forward PE | 18.51 |
| Dividend | 1.78 (1.73%) |
| Ex-Dividend Date | Oct 31, 2025 |
| Volume | 188 |
| Average Volume | 1,151 |
| Open | 101.00 |
| Previous Close | 101.62 |
| Day's Range | 101.00 - 103.42 |
| 52-Week Range | 101.00 - 172.60 |
| Beta | 0.96 |
| RSI | 28.75 |
| Earnings Date | Nov 4, 2025 |
About Zoetis
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other ph... [Read more]
Full Company ProfileFinancial Performance
In 2024, Zoetis's revenue was $9.26 billion, an increase of 8.33% compared to the previous year's $8.54 billion. Earnings were $2.49 billion, an increase of 6.06%.
Financial numbers in USD Financial StatementsNews
Zoetis Osteoarthritis Pain Franchise Needs A Reset: Analyst
As the animal health industry navigates a rapidly evolving landscape, companies are increasingly challenged to maintain their competitive edge through innovation and strategic adaptation. ZTS shares a...
Zoetis Osteoarthritis Pain Franchise Needs A Reset: Analyst
As the animal health industry navigates a rapidly evolving landscape, companies are increasingly challenged to maintain their competitive edge through innovation and strategic adaptation.
Zoetis (ZTS) Receives New Analyst Rating from Keybanc | ZTS Stock News
Zoetis (ZTS) Receives New Analyst Rating from Keybanc | ZTS Stock News
Zoetis (ZTS) Coverage Initiated with Sector Weight Rating by KeyBanc
Zoetis (ZTS) Coverage Initiated with Sector Weight Rating by KeyBanc
A Look Into Zoetis Inc's Price Over Earnings
In the current market session, Zoetis Inc. (NYSE: ZTS) price is at $117.53, after a 0.38% spike. However, over the past month, the stock fell by 20.42% , and in the past year, by 34.17% . Shareholder...
Zoetis to Participate in the Piper Sandler 37th Annual Healthcare Conference
Zoetis Inc. (NYSE:ZTS) will participate in the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4, 2025 at 9:30 a.m. ET. Kristin Peck, Chief Executive Officer and Wetteny Joseph, ...
Zoetis to Participate in the Piper Sandler 37th Annual Healthcare Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will participate in the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4, 2025 at 9:30 a.m. ET. ...
Zoetis to Host Innovation Webcast
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will host an Innovation Webcast at 8:30 a.m. ET on Tuesday, December 2, 2025, featuring Kristin Peck, Chief Executive O...
Zoetis (ZTS): Analyst Stifel Maintains Hold, Lowers Price Target to $130 | ZTS Stock News
Zoetis (ZTS): Analyst Stifel Maintains Hold, Lowers Price Target to $130 | ZTS Stock News
These stocks have been hit hard in 2025 but could surge by as much as 57% from here
Downtrodden names expected to come roaring back include Adobe, Block and Salesforce.
Zoetis: A High-Quality Compounder Now On Sale?
Zoetis (ZTS) the world's largest animal-health company, develops and manufactures medicines, vaccines, and diagnostics for both pets and livestock. The stock has come under pressure in recent months a...
Zoetis (ZTS) Analyst Rating Update: BTIG Lowers Price Target | ZTS Stock News
Zoetis (ZTS) Analyst Rating Update: BTIG Lowers Price Target | ZTS Stock News
Zoetis (ZTS): Morgan Stanley Lowers Price Target to $175 | ZTS Stock News
Zoetis (ZTS): Morgan Stanley Lowers Price Target to $175 | ZTS Stock News
The nut secret: 14 easy, delicious ways to eat more of these life-changing superfoods
A handful of nuts a day can help manage obesity and reduce your risk of cardiovascular disease, type 2 diabetes and some kinds of cancer. Yet most of us don’t get enough. Here’s a no-fuss guide to get...
Zoetis: Why I'm Still Holding The Stock But Advise Against New Positions
Zoetis Remains A Strong Buy Following Market Overreaction To Q3 Earnings
Zoetis Inc. trades at low valuations despite strong growth and pipeline. Click for my updated look at ZTS stock prospects following its Q3 earnings release.
Diamond Hill Capital's Strategic Moves: A Closer Look at Zoetis Inc.
Diamond Hill Capital's Strategic Moves: A Closer Look at Zoetis Inc.
JP Morgan Lowers Price Target for Zoetis (ZTS) to $200, Maintains Overweight Rating | ZTS Stock News
JP Morgan Lowers Price Target for Zoetis (ZTS) to $200, Maintains Overweight Rating | ZTS Stock News
I Used an AI Food Scanner App for 6 Weeks. This Is What It Taught Me About Carbs
The Zoe AI Meal Tracker app features barcode scanning, AI-powered food logging and a processed food risk scale to support healthy eating.
Decoding Zoetis Inc (ZTS): A Strategic SWOT Insight
Decoding Zoetis Inc (ZTS): A Strategic SWOT Insight
Zoetis (ZTS) Reports Strong Q3 2025 Revenue Growth
Zoetis (ZTS) Reports Strong Q3 2025 Revenue Growth
Zoetis Inc. (ZTS) Q3 2025 Earnings Call Transcript
Zoetis Inc. (ZTS) Q3 2025 Earnings Call November 4, 2025 8:30 AM ESTCompany ParticipantsSteven Frank - Vice President of Investor RelationsKristin Peck -...
Zoetis Inc (ZTS) Q3 2025 Earnings Call Highlights: Navigating Growth Amid Competitive Pressures
Zoetis Inc (ZTS) Q3 2025 Earnings Call Highlights: Navigating Growth Amid Competitive Pressures
Q3 2025 Zoetis Inc Earnings Call Transcript
Q3 2025 Zoetis Inc Earnings Call Transcript
Zoetis Stock Outlook Clouded By Rising Competitive Pressures
Animal health firm Zoetis Inc. (NYSE: ZTS) on Tuesday reported a third-quarter 2025 adjusted earnings per share of $1.70 . The company beat the consensus of $1.62. Adjusted net income was $754 millio...